GlycoNex (ROCO:4168) Short Interest

View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of GlycoNex's Short Interest

For the Biotechnology subindustry, GlycoNex's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlycoNex's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Short Interest distribution charts can be found below:

* The bar in red indicates where GlycoNex's Short Interest falls into.

GlycoNex Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221

Website

http://www.glyconex.com.tw

GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The Company also provides antibody research services to its academic and industrial clients. The other services provided by the firm include functional evaluation and antibody engineering. The company has two segments which are antibody new drugs and exclusive investment. It earns the majority of its revenue from the antibody new drugs segment.

GlycoNex Headlines

No Headlines